On December 29, BGH Capital announced that it was purchasing select assets from Aspen Pharmacare. The purchase price is A$2.37 billion (more than USD $1.585 billion).
The assets include Aspen’s Asia Pacific assets (Hong Kong, Taiwan, Malaysia and Philippines), excluding China. The assets constituted 18% of Aspen’s total revenue and 26% of its core profit for the year ended 30 June 2025, according to the company.
Aspen is a global specialty and branded multinational pharmaceutical company with a presence in both emerging and developed markets. It has approximately 9,100 employees at 69 established offices in more than 50 countries. It also operates 23 manufacturing facilities across 15 sites.
BGH Capital is a private equity group based in Melbourne, Australia. This is its first translation in the healthcare space, according to LevinPro HC data.
The assets were acquired to help Aspen Pharmacare to focus on producing GLP-1 drugs and bolster turnaround efforts. This transaction was also done to cut debt and boost capital, according to Aspen Pharmacare.
According to data in the LevinPro HC database, this transaction represents the 51st Pharmaceutical acquisition of the year. There were 66 Pharmaceutical deals in 2024. This deal also marks the fifth-largest Pharmaceutical deal of the year, by purchase price. The largest is GTCR’s acquisition of Zentiva for $4.8 billion.
